Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada; Heart and Stroke Foundation of Nova Scotia Endowed Chair in Cardiovascular Outcomes Research.
Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Am Heart J. 2018 Jul;201:149-157. doi: 10.1016/j.ahj.2018.04.008. Epub 2018 Apr 7.
The Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) is an investigator designed, prospective, randomized, un-blinded, cluster design clinical trial, conducted in the primary care setting of Nova Scotia, Canada. Its aim is to evaluate whether an electronic Clinical Decision Support System (CDSS) designed to assist both practitioners and patients with evidence-based management strategies for Atrial Fibrillation (AF) can improve process of care and outcomes in a cost-efficient manner as compared to usual AF care. At least 200 primary care providers are being recruited and randomized at the level of the practice to control (usual care) or intervention (eligible to access to CDSS) cohorts. Over 1,000 patients of participating providers with confirmed AF will be managed per their provider's respective assignment. The targeted primary clinical outcome is a reduction in the composite of unplanned cardiovascular (CV) or major bleeding hospitalizations and AF-related emergency department visits. Secondary clinical outcomes, process of care, patient and provider satisfaction as well as economic costs at the system and patient levels are being examined. The trial is anticipated to report in 2018.
《推进心房颤动社区治疗综合管理计划》(IMPACT-AF)是一项由研究者设计、前瞻性、随机、非盲、群组设计的临床试验,在加拿大新斯科舍省的初级保健环境中进行。其目的是评估一种旨在帮助医生和患者采用基于证据的心房颤动(AF)管理策略的电子临床决策支持系统(CDSS),是否可以以具有成本效益的方式改善护理流程和结果,与常规 AF 护理相比。正在招募至少 200 名初级保健提供者,并按实践水平随机分为对照组(常规护理)或干预组(有资格获得 CDSS)。每个参与的提供者将管理其提供者的各自分配的 1000 多名确诊 AF 患者。预定的主要临床结局是减少无计划的心血管(CV)或大出血住院和 AF 相关急诊就诊的复合事件。正在检查次要临床结局、护理流程、患者和提供者满意度以及系统和患者层面的经济成本。预计该试验将在 2018 年报告结果。